Navigation Links
Autism discovery paves way for early blood test and therapeutic options
Date:6/6/2013

r families."

Dr. Boccuto added, "We also see tremendous potential that these findings will aid in our understanding of the molecular and metabolic bases of autism. Once we have a clear vision of what has gone awry within the tryptophan metabolism pathways, we can develop therapies to target and correct those problems at the biochemical level."

L-tryptophan is one of twenty amino acids used by cells to make protein. It is one of eight amino acids that cannot be made by the body, so it must be obtained from the diet. More importantly, L-tryptophan plays an important role in brain development and function as it is the precursor of key neurochemicals such as serotonin and melatonin which have already been linked to behavioral and neurodevelopmental problems.

"This discovery leads us toward a possible unifying biochemical mechanism for ASDs which could ultimately lead to a treatment," shared Dr. Schwartz. "Now that we have additional evidence that the features of ASDs may be related to the metabolic pathways involving L-tryptophan, we can focus further studies on determining at what point along those pathways the disruption occurs, which may vary from one patient to another. With treatments that target various points along the pathway, a modality that works for one patient may not work for another."

GGC's autism research has been supported by funds from the South Carolina Department of Disabilities and Special Needs. Additional funding has been obtained from the National Institutes of Health to explore transitioning the research finding into a simple blood test for autism. Drs. Schwartz and Boccuto are currently evaluating the tryptophan metabolism in fresh blood samples from patients with ASDs and controls, utilizing customized Biolog plates.

"We are thrilled that Biolog's technology helped Dr. Schwartz in his pioneering research and that it has led to this breakthrough discovery," said Barry Bochner, PhD, CEO at Biolog, I
'/>"/>

Contact: Lori Bassett
lbassett@ggc.org
864-388-1061
Greenwood Genetic Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Over-produced autism gene alters synapses, affects learning and behavior in mice
2. Bigger birth weight babies at greater risk of autism
3. Epigenetic changes shed light on biological mechanism of autism
4. In autism, age at diagnosis depends on specific symptoms
5. Autism in black and white: NIH grant helps scientist study disorder in African Americans
6. Atypical brain circuits may cause slower gaze shifting in infants who later develop autism
7. Folic acid lowers risk of autism
8. Speech emerges in children with autism and severe language delay at greater rate than thought
9. Ultrasound reveals autism risk at birth
10. Researcher uncovers potential cause, biomarker for autism and proposes study to investigate theory
11. UCI research turns the corner on autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... supplements during pregnancy is not only safe for mother and ... to results of a randomized controlled study to be presented ... British Columbia, Canada. In the 1950s and ,60s, ... according to Carol L. Wagner, MD, lead author of the ...
... 2010) Natural S-equol, a novel soy germ-based compound, ... flushes in the dietary supplement SE5-OH, which is under ... efficacy data from studies using an animal model presented ... SE5-OH is in advanced studies in menopausal women, and ...
... , Using DNA samples and images from Earth-orbiting ... Society, the American Museum of Natural History, and ... franciscanaa poorly known coastal dolphin species of eastern ... conserve them. The study, one of ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 2Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 3Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 4Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 5Satellites, DNA and dolphins 2Satellites, DNA and dolphins 3Satellites, DNA and dolphins 4
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... Pa., Nov. 5 VWR Funding, Inc. (formerly CDRV,Investors, Inc.) the parent company of ... call on Thursday,November 15th to discuss its financial results for the quarter ended September,30, ... Ballbach, Chairman, President and CEO ... ...
... - Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 -,- ... ... Diluted Share - - Company Provides ... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer and distributor of,plant-based ...
... SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. (Nasdaq: ... the third quarter,ended September 30, 2007. Revenues ... $26.8 million,compared to $23.5 million for the comparable ... to 2007 was primarily due to revenue recognition,associated ...
Cached Biology Technology:VWR Funding, Inc. to Hold Third Quarter 2007 Financial Results Conference Call 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8